Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 64 of 64 results for metastatic prostate cancer

  1. Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)

    NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .

    Medtech innovation briefing
    Published
    4 October 2022

  2. Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)

    This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.

    Technology appraisal guidance
    Published
    23 February 2015

  3. NICE final draft guidance recommends olaparib for early breast cancer and metastatic prostate cancer following new commercial deals

    Ground-breaking commercial deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit in final draft guidance published today (6 April 2023) by NICE that recommends it for some types of early breast cancer and advanced prostate cancer.

    News
    Published
    6 April 2023

  4. Behind the Headlines - Prostate cancer drug decision a 'cruel twist'

    We take a closer look at media coverage that claims our prostate cancer drug decision is a 'cruel twist' for patients.

    News
    Published
    4 February 2014